Robert L. Hamlin

Robert L. Hamlin's work centers on cardiovascular physiology and pharmacology, largely using animal models (dogs, pigs, rabbits, sheep, rats) to study heart function, heart failure, arrhythmias, and myocardial ischemia. Much of the research supports drug development and testing, including studies on heart medications like pimobendan and dapagliflozin, as well as new device-based approaches to detecting and treating cardiac disease. The work spans veterinary cardiology, translational cardiovascular models for human disease, and pharmacological/toxicological methods.

Publication output has declined from a peak of 17 papers in 2017 to a lower, fluctuating level of about 2-7 papers per year in recent years, averaging around 3 per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026